JUL 16, 2020 7:42 AM PDT

Cancer Vaccine Charges Toward the Clinic

WRITTEN BY: Tara Fernandez

Kristen Radford, a professor at Australia’s University of Queensland is leading a scientific research team that's developing the next generation of therapeutic cancer vaccines. Their vaccine, which showed promising results in preclinical trials, has hit a new milestone as the team now plans to test its efficacy in human clinical trials.

According to Radford, this experimental vaccine has immense potential in treating a wide spectrum of malignancies. "We are hoping this vaccine could be used to treat blood cancers, such as myeloid leukemia, non-Hodgkin's lymphoma, multiple myeloma, and pediatric leukemias, plus solid malignancies including breast, lung, renal, ovarian, and pancreatic cancers, and glioblastoma," she said.

The vaccine is a chimera, made up of human antibodies that are genetically fused to a tumor-specific protein called Wilms’ tumor 1, or WT1. The WT1 protein is one of the most studied tumor-associated antigens, meaning that the presence of WT1 on tumors can flag down circulating immune cells to target and destroy the cancerous cells. Due to its high immunogenicity, WT1 is a prime target for therapeutic cancer vaccine development.

Vaccines can train the immune system to recognize and eliminate invading pathogens and malignant cells. There are currently two types of cancer vaccines, ones that either prevent cancer development or vaccines that are applied therapeutically to wipe out residual tumors after therapy and prevent cancer from recurring. Most of the therapeutic vaccines are still in development and not widely available outside of a clinical trial setting.

Radford and colleagues believe that this new cancer vaccine has an edge over other similar treatments in development.

Speaking on these advantages, she commented, "First, it can be produced as an 'off the shelf' clinical-grade formulation, which circumvents the financial and logistical issues associated with patient-specific vaccines."

"Secondly, this prototype vaccine targets the key tumor cells required for the initiation of tumor-specific immune responses, thereby maximizing the potential effectiveness of treatment, while minimizing potential side effects.”

“We are very happy to see our research published in a prestigious journal, and we hope our continued work towards finding a safe and effective cancer vaccine will benefit cancer patients in the future,” added Radford, whose study has recently been published in the highly ranked journal, Clinical and Translational Immunology.

 

 

Sources: Clinical and Translational Immunology, Translational Research Institute.


 

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
JUN 20, 2020
Cell & Molecular Biology
Antibodies Isolated From COVID-19 Patients Show Therapeutic Potential
JUN 20, 2020
Antibodies Isolated From COVID-19 Patients Show Therapeutic Potential
Communities worldwide are emerging from lockdowns due to the SARS-CoV-2 pandemic virus, and cases are rising.
JUN 25, 2020
Immunology
The Protein That Orchestrates Cells' Dance of Death
JUN 25, 2020
The Protein That Orchestrates Cells' Dance of Death
When cells become diseased or infected, a “suicide switch” is triggered, preventing neighboring cells from b ...
JUL 29, 2020
Drug Discovery & Development
Will We Have a COVID-19 Vaccine by Year-End?
JUL 29, 2020
Will We Have a COVID-19 Vaccine by Year-End?
This week, pharmaceutical companies Moderna and Pfizer launched giant Phase III 30,000-subject trials for their COVID-19 ...
AUG 17, 2020
Immunology
Nervous Protein Neuromedin B May Prevent Immune Reactivity
AUG 17, 2020
Nervous Protein Neuromedin B May Prevent Immune Reactivity
A protein produced by the nervous system seems to play a role in regulating the immune system. For people with inflammat ...
SEP 16, 2020
Immunology
Depression, but Not Anxiety, Causes Inflammation and Metabolic Imbalances
SEP 16, 2020
Depression, but Not Anxiety, Causes Inflammation and Metabolic Imbalances
Scientists have discovered that depressed individuals show higher levels of inflammation as well as elevated fat concent ...
SEP 23, 2020
Immunology
Gene That Fuels Antibody Factories Discovered
SEP 23, 2020
Gene That Fuels Antibody Factories Discovered
Antibodies are Y-shaped proteins that play a central role in the immune system’s arsenal of germ-busting weapons. ...
Loading Comments...